Cook Biotech: Cook, AcuityBio ink deal for lung cancer drug technology

Cook Biotech will collaborate with drug-delivery maker AcuityBio on Acuity's lead lung cancer product, the companies said today. Acuity's ABC103 will use Cook Biotech's proprietary extracellular matrix (ECM) technology. ABC103 is a platform technology designed for localized, sustained drug delivery to prevent post-surgical lung cancer recurrence. It combines approved/ cleared surgical staple-line buttress, drug-eluting polymers and [...]The post Cook, AcuityBio ink deal for lung cancer drug technology appeared first on MassDevice.